Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome
Open Access
- 1 May 2010
- journal article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 298 (5), E1072-E1077
- https://doi.org/10.1152/ajpendo.00728.2009
Abstract
The proinflammatory and proatherogenic mediator, soluble CD40 ligand (CD40L), is increased in the metabolic syndrome (MS) and released from platelets. We hypothesized that adiponectin modulates platelet function, and we sought to evaluate the association of adiponectin and sCD40L levels with platelet aggregation in MS and the effects of adiponectin on platelet aggregation and activation. Platelet aggregation and circulating adiponectin, sCD40L and P-selectin were determined in 30 controls and 30 patients with MS. Also, in vitro studies were performed in platelet-rich plasma from nine healthy volunteers. Adiponectin receptors were demonstrated by Western blotting and flow cytometry. ADP and epinephrine platelet aggregation was measured after preincubation with adiponectin. sCD40L and P-selectin secretion was measured in the supernatants by ELISA. Patients with MS had higher sCD40L and P-selectin than controls (5.96 ± 0.50 vs. 4.28 ± 0.41 ng/ml, P < 0.05, and 151 ± 8 vs. 122 ± 9 ng/ml, P < 0.05). By contrast, adiponectin was lower in patients with MS than in controls (5.25 ± 0.30 vs. 7.35 ± 0.34 μg/ml, P < 0.001). Higher platelet aggregation was found in MS. Adiponectin inversely correlated with P-selectin ( R = −0.35, P = 0.009), sCD40L ( r = −0.24, P = 0.05) and epinephrine and collagen induced aggregation ( r = −0.80, P = 0.005; r = −0.70, P = 0.011). Platelets express the receptors for adiponectin. Platelet aggregatory response to epinephrine and ADP significantly decreased following preincubation with adiponectin (96 ± 4 vs. 23 ± 3%, P < 0.001, and 102 ± 9 vs. 85 ± 9%, P = 0.004). Adiponectin prevented platelet sCD40L release (1.63 ± 0.15 vs. 2.04 ± 0.20 ng/ml, P < 0.001). Enhanced platelet aggregation and activation markers are found in MS associated with low adiponectin concentrations. Novel evidence is provided demonstrating that adiponectin has antithrombotic properties, since it inhibits platelet aggregation and platelet activation.Keywords
This publication has 29 references indexed in Scilit:
- The association between pulse wave velocity and metabolic syndrome and adiponectin in patients with impaired fasting glucose: Cardiovascular risks and adiponectin in IFGDiabetes Research and Clinical Practice, 2009
- Association Between Increased Platelet P-Selectin Expression and Obesity in Patients With Type 2 DiabetesDiabetes Care, 2009
- Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartanNephrology Dialysis Transplantation, 2009
- Globular adiponectin increases cGMP formation in blood platelets independently of nitric oxideJournal of Thrombosis and Haemostasis, 2008
- Hypertension, aortic sclerosis and the prothrombotic state: understanding the complex interactionJournal of Human Hypertension, 2008
- Association of hematological parameters with clustered components of metabolic syndrome among professional and office workers in Bangkok, ThailandDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2007
- Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end productsDiabetes and Vascular Disease Research, 2005
- Association between obesity and a prothrombotic state: the Framingham Offspring StudyThrombosis and Haemostasis, 2004
- Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic PatientsCirculation, 2003
- Enhanced Risk of Thromboembolic Disease in Hypertension from Platelet Hyperfunction and Decreased Fibrinolytic ActivityJournal of Cardiovascular Pharmacology, 1992